Compare Snap On Incorporated (SNA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs Twist Bioscience Corp — how do they compare? Snap On Incorporated trades at $406.52 (market cap $21.06B), while Twist Bioscience Corp trades at $89.33 (market cap $5.45B). The key difference: Snap On Incorporated is far larger — about 3.9× Twist Bioscience Corp's market cap, and Snap On Incorporated pays a 2.4% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SNA | TWST | |
|---|---|---|
Market Cap | $21.06B | $5.45B |
Sector | Technology | Health |
52-Week High | $414.97 | $102.88 |
52-Week Low | $317.79 | $24.16 |
Enterprise Value | $20.58B | $5.37B |
Dividend Yield | 2.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, near the consensus price target of $407.50. The stock shows a bullish technical trend with strong moving average signals and support at $403. Fundamentally, SNA maintains robust profitability with a 19.6% net income margin and 17.83% ROE, though Q1 2026 EPS slightly missed expectations. Recent acquisitions like Diesel Laptops for $100 million highlight strategic growth initiatives.
Outlook remains positive with 65% analyst buy ratings and a dividend yield supported by consistent cash flow. Key risks include margin pressures and muted revenue growth. The upcoming Q2 2026 earnings report on July 23, 2026, will be critical for validating current valuation multiples amid economic uncertainty.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
